Emerging biomarkers—including beta-2-microglobulin (B2M), beta-trace protein (BTP), fibrosis-related markers, and multi-biomarker panels—offer improved diagnostic precision, risk stratification, and personalized treatment strategies in CKD management [60,61,62]. This evidence concerns the gene B2M and chronic kidney disease.